28-Oct-2026 08:42:35
JEFFERIES ON MANKIND PHARMA ; BUY | TP ₹2,900
• Analyst Day highlights focus on expanding the company's chronic therapy portfolio and strengthening long-term growth. • India business aims to increase chronic segment market share through new specialty divisions, product launches and scaling established brands. • Consumer healthcare growth expected to remain subdued in the near term amid leadership transition. • Medium-term priorities include expanding wellness products, strengthening new-age distribution channels and switching prescription (Rx) products to over-the-counter (OTC) categories. • ACTx represents a strategic investment in an advanced oncology platform, backed by a team with proven expertise in cell and gene therapies. • Jefferies maintains BUY rating on Mankind Pharma with a target price of ₹2,900, supported by its chronic therapy expansion and long-term growth initiatives.
MANKIND PHARMA LIMITED